Lymphoplasmacytic lymphoma risk factors: Difference between revisions
Created page with "__NOTOC__ {{Lymphoplasmacytic lymphoma}} {{CMG}}; {{AE}} ==Overview== There are no established risk factors for [disease name]. OR The most potent risk factor in the devel..." |
Sara Mohsin (talk | contribs) |
||
Line 19: | Line 19: | ||
==Risk Factors== | ==Risk Factors== | ||
Common risk factors in the development of Waldenström macroglobulinemia include:<ref name="RF">Waldenström's macroglobulinemia. American Cancer Society (2015)http://www.cancer.org/cancer/waldenstrommacroglobulinemia/detailedguide/waldenstrom-macroglobulinemia-risk-factors Accessed on November 6, 2015</ref> | |||
* [[Monoclonal gammopathy of undetermined significance]] (MGUS): | |||
** Pre-existing [[monoclonal gammopathy of undetermined significance]] is the most common [[Risk factors|risk factor]], associated with 40 times more likelihood of developing Waldenström's macroglobulinemia. | |||
* [[Heredity]]: | |||
** Patients with Waldenström's macroglobulinemia usually have a close/first-degree relative with the disease or with a related [[B-cell leukemia|B-cell disease]], such as [[MGUS]] or certain types of [[lymphoma]] or [[leukemia]].<ref name="pmid16357024">{{cite journal| author=Treon SP, Hunter ZR, Aggarwal A, Ewen EP, Masota S, Lee C et al.| title=Characterization of familial Waldenstrom's macroglobulinemia. | journal=Ann Oncol | year= 2006 | volume= 17 | issue= 3 | pages= 488-94 | pmid=16357024 | doi=10.1093/annonc/mdj111 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16357024 }} </ref><ref name="pmid17785558">{{cite journal| author=McMaster ML, Csako G, Giambarresi TR, Vasquez L, Berg M, Saddlemire S et al.| title=Long-term evaluation of three multiple-case Waldenstrom macroglobulinemia families. | journal=Clin Cancer Res | year= 2007 | volume= 13 | issue= 17 | pages= 5063-9 | pmid=17785558 | doi=10.1158/1078-0432.CCR-07-0299 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17785558 }} </ref><ref name="pmid18703425">{{cite journal| author=Kristinsson SY, Björkholm M, Goldin LR, McMaster ML, Turesson I, Landgren O| title=Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia patients: a population-based study in Sweden. | journal=Blood | year= 2008 | volume= 112 | issue= 8 | pages= 3052-6 | pmid=18703425 | doi=10.1182/blood-2008-06-162768 | pmc=2569164 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18703425 }} </ref> | |||
* [[Hepatitis C]]: | |||
** Patients with chronic [[hepatitis C]] infection have an overall 20-30% increased risk for developing non-Hodgkin lymohoma and 3-fold increased risk for WM.<ref name="pmid18703425">{{cite journal| author=Kristinsson SY, Björkholm M, Goldin LR, McMaster ML, Turesson I, Landgren O| title=Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia patients: a population-based study in Sweden. | journal=Blood | year= 2008 | volume= 112 | issue= 8 | pages= 3052-6 | pmid=18703425 | doi=10.1182/blood-2008-06-162768 | pmc=2569164 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18703425 }} </ref><ref name="pmid18809818">{{cite journal| author=Koshiol J, Gridley G, Engels EA, McMaster ML, Landgren O| title=Chronic immune stimulation and subsequent Waldenström macroglobulinemia. | journal=Arch Intern Med | year= 2008 | volume= 168 | issue= 17 | pages= 1903-9 | pmid=18809818 | doi=10.1001/archinternmed.2008.4 | pmc=2670401 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18809818 }} </ref><ref name="pmid18387498">{{cite journal| author=de Sanjose S, Benavente Y, Vajdic CM, Engels EA, Morton LM, Bracci PM et al.| title=Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium. | journal=Clin Gastroenterol Hepatol | year= 2008 | volume= 6 | issue= 4 | pages= 451-8 | pmid=18387498 | doi=10.1016/j.cgh.2008.02.011 | pmc=3962672 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18387498 }} </ref> | |||
* [[Autoimmune Disease|Autoimmune Diseases]]: | |||
**Personal and family history of autoimmune diseases with autoantibodies leads to 2-3 fold higher risk of developing WM, especially elevated risks are associated with following: | |||
***HIV.<ref name="pmid18809818">{{cite journal| author=Koshiol J, Gridley G, Engels EA, McMaster ML, Landgren O| title=Chronic immune stimulation and subsequent Waldenström macroglobulinemia. | journal=Arch Intern Med | year= 2008 | volume= 168 | issue= 17 | pages= 1903-9 | pmid=18809818 | doi=10.1001/archinternmed.2008.4 | pmc=2670401 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18809818 }} </ref> | |||
=== | ***Rickettsiosis.<ref name="pmid18809818">{{cite journal| author=Koshiol J, Gridley G, Engels EA, McMaster ML, Landgren O| title=Chronic immune stimulation and subsequent Waldenström macroglobulinemia. | journal=Arch Intern Med | year= 2008 | volume= 168 | issue= 17 | pages= 1903-9 | pmid=18809818 | doi=10.1001/archinternmed.2008.4 | pmc=2670401 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18809818 }} </ref> | ||
* | ***[[Sjögren syndrome]].<ref name="pmid20181958">{{cite journal| author=Kristinsson SY, Koshiol J, Björkholm M, Goldin LR, McMaster ML, Turesson I et al.| title=Immune-related and inflammatory conditions and risk of lymphoplasmacytic lymphoma or Waldenstrom macroglobulinemia. | journal=J Natl Cancer Inst | year= 2010 | volume= 102 | issue= 8 | pages= 557-67 | pmid=20181958 | doi=10.1093/jnci/djq043 | pmc=2857799 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20181958 }} </ref><ref name="pmid18263783">{{cite journal| author=Ekström Smedby K, Vajdic CM, Falster M, Engels EA, Martínez-Maza O, Turner J et al.| title=Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. | journal=Blood | year= 2008 | volume= 111 | issue= 8 | pages= 4029-38 | pmid=18263783 | doi=10.1182/blood-2007-10-119974 | pmc=2288717 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18263783 }} </ref> | ||
* | ***Autoimmune hemolytic anemia.<ref name="pmid20181958">{{cite journal| author=Kristinsson SY, Koshiol J, Björkholm M, Goldin LR, McMaster ML, Turesson I et al.| title=Immune-related and inflammatory conditions and risk of lymphoplasmacytic lymphoma or Waldenstrom macroglobulinemia. | journal=J Natl Cancer Inst | year= 2010 | volume= 102 | issue= 8 | pages= 557-67 | pmid=20181958 | doi=10.1093/jnci/djq043 | pmc=2857799 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20181958 }} </ref><ref name="pmid18263783">{{cite journal| author=Ekström Smedby K, Vajdic CM, Falster M, Engels EA, Martínez-Maza O, Turner J et al.| title=Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. | journal=Blood | year= 2008 | volume= 111 | issue= 8 | pages= 4029-38 | pmid=18263783 | doi=10.1182/blood-2007-10-119974 | pmc=2288717 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18263783 }} </ref> | ||
** | ***Sarcoidosis.<ref name="pmid16985251">{{cite journal| author=Landgren O, Engels EA, Pfeiffer RM, Gridley G, Mellemkjaer L, Olsen JH et al.| title=Autoimmunity and susceptibility to Hodgkin lymphoma: a population-based case-control study in Scandinavia. | journal=J Natl Cancer Inst | year= 2006 | volume= 98 | issue= 18 | pages= 1321-30 | pmid=16985251 | doi=10.1093/jnci/djj361 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16985251 }} </ref> | ||
** | ***SLE.<ref name="pmid18263783">{{cite journal| author=Ekström Smedby K, Vajdic CM, Falster M, Engels EA, Martínez-Maza O, Turner J et al.| title=Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. | journal=Blood | year= 2008 | volume= 111 | issue= 8 | pages= 4029-38 | pmid=18263783 | doi=10.1182/blood-2007-10-119974 | pmc=2288717 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18263783 }} </ref> | ||
* | * [[Allergic]] conditions: | ||
**[[Hay fever]] is also known to be associated with increased risk of WM. | |||
=== | |||
* | |||
**[ | |||
==References== | ==References== |
Revision as of 15:49, 12 February 2019
Lymphoplasmacytic lymphoma Microchapters |
Differentiating Lymphoplasmacytic Lymphoma from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Lymphoplasmacytic lymphoma risk factors On the Web |
American Roentgen Ray Society Images of Lymphoplasmacytic lymphoma risk factors |
Risk calculators and risk factors for Lymphoplasmacytic lymphoma risk factors |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
There are no established risk factors for [disease name].
OR
The most potent risk factor in the development of [disease name] is [risk factor 1]. Other risk factors include [risk factor 2], [risk factor 3], and [risk factor 4].
OR
Common risk factors in the development of [disease name] include [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4].
OR
Common risk factors in the development of [disease name] may be occupational, environmental, genetic, and viral.
Risk Factors
Common risk factors in the development of Waldenström macroglobulinemia include:[1]
- Monoclonal gammopathy of undetermined significance (MGUS):
- Pre-existing monoclonal gammopathy of undetermined significance is the most common risk factor, associated with 40 times more likelihood of developing Waldenström's macroglobulinemia.
- Hepatitis C:
- Patients with chronic hepatitis C infection have an overall 20-30% increased risk for developing non-Hodgkin lymohoma and 3-fold increased risk for WM.[4][5][6]
- Autoimmune Diseases:
- Allergic conditions:
- Hay fever is also known to be associated with increased risk of WM.
References
- ↑ Waldenström's macroglobulinemia. American Cancer Society (2015)http://www.cancer.org/cancer/waldenstrommacroglobulinemia/detailedguide/waldenstrom-macroglobulinemia-risk-factors Accessed on November 6, 2015
- ↑ Treon SP, Hunter ZR, Aggarwal A, Ewen EP, Masota S, Lee C; et al. (2006). "Characterization of familial Waldenstrom's macroglobulinemia". Ann Oncol. 17 (3): 488–94. doi:10.1093/annonc/mdj111. PMID 16357024.
- ↑ McMaster ML, Csako G, Giambarresi TR, Vasquez L, Berg M, Saddlemire S; et al. (2007). "Long-term evaluation of three multiple-case Waldenstrom macroglobulinemia families". Clin Cancer Res. 13 (17): 5063–9. doi:10.1158/1078-0432.CCR-07-0299. PMID 17785558.
- ↑ 4.0 4.1 Kristinsson SY, Björkholm M, Goldin LR, McMaster ML, Turesson I, Landgren O (2008). "Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia patients: a population-based study in Sweden". Blood. 112 (8): 3052–6. doi:10.1182/blood-2008-06-162768. PMC 2569164. PMID 18703425.
- ↑ 5.0 5.1 5.2 Koshiol J, Gridley G, Engels EA, McMaster ML, Landgren O (2008). "Chronic immune stimulation and subsequent Waldenström macroglobulinemia". Arch Intern Med. 168 (17): 1903–9. doi:10.1001/archinternmed.2008.4. PMC 2670401. PMID 18809818.
- ↑ de Sanjose S, Benavente Y, Vajdic CM, Engels EA, Morton LM, Bracci PM; et al. (2008). "Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium". Clin Gastroenterol Hepatol. 6 (4): 451–8. doi:10.1016/j.cgh.2008.02.011. PMC 3962672. PMID 18387498.
- ↑ 7.0 7.1 Kristinsson SY, Koshiol J, Björkholm M, Goldin LR, McMaster ML, Turesson I; et al. (2010). "Immune-related and inflammatory conditions and risk of lymphoplasmacytic lymphoma or Waldenstrom macroglobulinemia". J Natl Cancer Inst. 102 (8): 557–67. doi:10.1093/jnci/djq043. PMC 2857799. PMID 20181958.
- ↑ 8.0 8.1 8.2 Ekström Smedby K, Vajdic CM, Falster M, Engels EA, Martínez-Maza O, Turner J; et al. (2008). "Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium". Blood. 111 (8): 4029–38. doi:10.1182/blood-2007-10-119974. PMC 2288717. PMID 18263783.
- ↑ Landgren O, Engels EA, Pfeiffer RM, Gridley G, Mellemkjaer L, Olsen JH; et al. (2006). "Autoimmunity and susceptibility to Hodgkin lymphoma: a population-based case-control study in Scandinavia". J Natl Cancer Inst. 98 (18): 1321–30. doi:10.1093/jnci/djj361. PMID 16985251.